Chronic lymphocytic leukemia and autoimmunity: A systematic review

Haematologica

Volumn 96, Issue 5, 2011, Pages 752-761

  Hodgson, Kate ^a   Ferrer, Gerardo ^a   Montserrat, Emili ^a   Moreno, Carol ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL; LYMPHOCYTOSIS; PROGNOSIS; SYSTEMATIC REVIEW;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MODELS, IMMUNOLOGICAL; THROMBOCYTOPENIA;

EID: 79955730789     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036152     Document Type: Article

References (125)

1. Swerdlow S, International Agency for Research on C, World Health O. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon France: International Agency for Research on Cancer 4th ed. 2008.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
3. Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J. 1966;94(19):1005-10.
4. Dameshek W. Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes. Blood. 1967;29(4):S566-84.
5. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Path. 1986;39(7):713-6.
6. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993;81(10):2475-87.
7. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005 24;352(8):804-15.
8. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. 2009;339:b2700.
10. Ebbe S, Wittels B, Dameshek W. Autoimmune thrombocytopenic purpura (ITP type) with chronic lymphocytic leukemia. Blood. 1962;19:23-37.
11. Lewis FB, Schwartz RS, Dameshek W. Xradiation and alkylating agents as possible trigger mechanisms in the autoimmune complications of malignant lymphophroliferative disease. Clin Exp Immunol. 1966; 1(1):3-11.
12. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95(9):2786-92.
13. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141(5): 615-21.
14. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008:450-6.
15. Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, et al. Autoimmune cytopenias in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010; 116(23):4771-6.
16. Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol. 1987;67(2):235-9.
17. Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al. Relationship between autoimmune phenomena and disease stage and therapy in Bcell chronic lymphocytic leukemia. Haematologica. 2006;91(12):1689-92.
18. Visco C, Ruggeri M, Laura Evangelista M, Stasi R, Zanotti R, Giaretta I, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111(3):1110-6.
19. Narra K, Borghaei H, Al-Saleem T, Höglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res. 2006;30(1):109-14.
20. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):230-9.
21. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab-- incidence and predictors. Br J Haematol. 2007;136(6):800-5.
22. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111(4):1820-6.
23. Conley CL, Misiti J, Laster AJ. Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. Medicine. 1980;59(5):323-34.
24. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003;74(1):1-8.
25. Duek A, Shvidel L, Braester A, Berrebi A. Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J. 2006;8(12):828-31.
26. Zent CS, Shanafelt T. Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. Leukemia & Lymphoma. 2009;50(6):863-4.
27. Vanura K, Le T, Esterbauer H, Späth F, Porpaczy E, Shehata M, et al. Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica. 2008;93(12):1912-6.
28. Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, et al. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood. 2006;108(1):292-6.
29. Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139(5):791-8.
30. Söderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006;42(17): 3028-33.
31. Hemminki K, Li X, Sundquist J, Sundquist K. Cancer risks in ulcerative colitis patients. Int J Cancer. 2008;123(6):1417-21.
32. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med. 2008;264 (6):514-27.
33. Slager SL, Kay NE, Fredericksen ZS, Wang AH, Liebow M, Cunningham JM, et al. Susceptibility genes and B-chronic lymphocytic leukaemia. Br J Haematol. 2007;139 (5):762-71.
34. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10): 1204-10.
35. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17(R2): R116-21.
36. Caligaris-Cappio F. Relationship be tweenautoimmunity and immunodeficiency in CLL. Hematol Cell Ther. 1997;39(S1):S13-6.
37. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F. From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev. 2007;7(2): 127-31.
38. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625-38.
39. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-94.
40. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011;117(6):1781-91.
41. Phillips JA, Mehta K, Fernandez C, Raveché ES. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res. 1992;52(2):437-43.
42. Youinou P, Renaudineau Y. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev. 2007;7 (2):149-54.
43. Hervé M, Xu K, Ng Y-S, Wardemann H, Albesiano E, Messmer BT, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest. 2005;115(6): 1636-43.
44. Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol. 2010;20(6): 377-83.
45. Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008;14(11-12):665-74.
46. Lanemo Myhrinder A, Hellqvist E, Sidorova E, Söderberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111 (7):3838-48.
47. Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed non-muscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115(19):3907-15.
48. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491-8.
49. Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase- labeled antibodies. I. Detection and quantitation of light chain determinants. Blood. 1974;43(6):789-95.
50. Payelle-Brogard B, Magnac C, Alcover A, Roux P, Dighiero G. Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia. Br J Haematol. 2002;118(4):976-85.
51. Vuillier F, Dumas G, Magnac C, Prevost MC, Lalanne AI, Oppezzo P, et al. Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. Blood. 2005;105(7):2933-40.
52. Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ. Aberrant B Cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Nat Acad Sci USA. 2000;97(10):5504-9.
53. Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, Budman DR, et al. Production of autoantibodies by CD5- expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989;169(1):255-68.
54. Beaume A, Brizard A, Dreyfus B, Preud'homme JL. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood. 1994;84(4): 1216-9.
55. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105(5):2007- 15.
56. Galletti J, Cañones C, Morande P, Borge M, Oppezzo P, Geffner J, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol. 2008;181(5):3674-83.
57. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in BCLL. Ann Oncol. 2004;15(6):853-7.
58. Görgün G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797-805.
59. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. 1998;91(11):4273-81.
60. Sampalo A, Brieva JA. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Leuk Lymphoma. 2002;43(4): 881-4.
61. Rebmann V, Nückel H, Dührsen U, Grosse- Wilde H. HLA-G in B-chronic lymphocytic leukaemia: Clinical relevance and functional implications. Semin Cancer Biol. 2007;17 (6):430-5.
62. Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol. 2010;20(6):431-8.
63. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica. 2009;94(9): 1198-202.
64. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 1996;10(9): 1509-13.
65. Shvidel L, Vorst E, Berrebi A. Complement values in B chronic lymphocytic leukemia: prognostic significance and correlation with cell maturation stage. Leukemia. 1998;12(4):635-6.
66. Itälä M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol. 1996;57(1):46-53.
67. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22(5):998-1006.
68. Visco C, Giaretta I, Ruggeri M, Madeo D, Tosetto A, Rodeghiero F. Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia. 2007;21(5):1092-3.
69. Rossi D, Gaidano G. Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia. Haematologica. 2010;95(12):1992-5.
70. Mittal S, Blaylock MG, Culligan DJ, Barker RN, Vickers MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008;93(1):151-2.
71. Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831-8.
72. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol. 1992;3(2): 171-2.
73. Tosti S, Caruso R, D'Adamo F, Picardi A, Ali Ege M, Girelli G, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine- based treatment. Ann Hematol. 1992;65(5):238-9.
74. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, et al. Fludarabinerelated autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995;91(2):341- 4.
75. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11 (1):7-13.
76. Byrd JC, Hertler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol. 1995;6(3):300-1.
77. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
78. Visco C, Novella E, Peotta E, Paolini R, Giaretta I, Rodeghiero F. Autoimmune haemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica. 2010;95(7): 1230-2.
79. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-34.
80. Zent CS, Kay NE. Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL). Baillieres Best Pract Res Clin Haematol. 2010;23(1):47-59.
81. Gribben JG. How I treat CLL up front. Blood. 2010;115(2):187-97.
82. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma. 2007;48(6):1072-80.
83. Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol. 2002;69(3):232-3.
84. Pamuk GE, Turgut B, Demir M, Tezcan F, Vural O. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. Am J Hematol. 2006;81 (8):631-3.
85. Gentile M, Lucia E, Iorio C, Vigna E, Mazzone C, Morelli R, et al. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab- based therapy in a chronic lymphocytic leukemia patient. Cancer Chemother Pharmacol. 2008;62(4):741-3.
86. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141(2):149-69.
87. D'Arena G, Capalbo S, Laurenti L, Del Poeta G, Nunziata G, Deaglio S, et al. Chronic Lymphocytic Leukemia- Associated Immune Thrombocytopenia Treated with Rituximab: A Retrospective Study of 21 Patients. Eur J Haematol. 2010;85(6):502-7.
88. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21(3):511-4.
89. Laurenti L, Tarnani M, Efremov DG, Chiusolo P, De Padua L, Sica S, et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia. 2007;21(8):1819-21.
90. Royer B, Vaida I, Etienne A, Garidi R, Damaj G, Marolleau JP. Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab. Leukemia. 2007;21(8):1841-2.
91. Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia. 2010;24(5):1096-8.
92. Kaufman M, Limaye SA, Driscoll N, Johnson C, Caramanica A, Lebowicz Y, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(6):892-9.
93. Bowen DA, Call TG, Shanafelt TD, Kay NE, Schwager SM, Reinalda MS, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010;51(4):620-7.
94. Rossignol J, Michallet AS, Oberic L, Picard M, Garon A, Willekens C, et al. Rituximabcyclophosphamide- dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia. 2010 Dec 3. [Epub ahead of print].
95. Parker AC, Bennett M. Pernicious anaemia and lymphoproliferative disease. Scand J Haematol. 1976;17(5):395-7.
96. Ruvidić R, Bosković D. [Chronic lymphocytic leukemia complicated by pernicious anemia during long-term remission]. Srpski Arhiv Za Celokupno Lekarstvo. 1990;118 (11-12):495-7.
97. Drake WM, Monson JP, Trainer PJ, Sharief M, Dick JP, Kelsey SM. Acute polyneuropathy with chronic lymphocytic leukaemia and paraproteinaemia: response to chlorambucil and prednisolone. J Neurol Neurosur Psychiatr. 1998;64(4):564.
98. Mitsui Y, Kusunoki S, Hiruma S, Akamatsu M, Kihara M, Hashimoto S, et al. Sensorimotor polyneuropathy associated with chronic lymphocytic leukemia, IgM antigangliosides antibody and human T-cell leukemia virus I infection. Muscle Nerve. 1999;22(10):1461-5.
99. D'Arena G, Vigliotti ML, Pizza V, Tartarone A, Volpe G, Iodice G, et al. Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2004;45(7): 1489-90.
100. Taylor HG, Nixon N, Sheeran TP, Dawes PT. Rheumatoid arthritis and chronic lymphatic leukaemia. Clin Exp Rheumatol. 1989;7(5):529-32.
101. Voulgari PV, Vartholomatos G, Kaiafas P, Bourantas KL, Drosos AA. Rheumatoid arthritis and B-cell chronic lymphocytic leukemia. Clin Exp Rheumatol. 2002;20(1): 63-5.
102. Onal IK, Ozçakar L, Dizdar O, Büyükasik Y, Dündar S. Seropositive arthritis in chronic lymphocytic leukemia: a remark on B cell-mediated autoimmunity. Rheumatol Int. 2005;25(7):569-70.
103. Lehner-Netsch G, Barry A, Delage JM. [Leukemias and autoimmune diseases: Sjogren's syndrome and hemolytic anemia associated with chronic lymphocytic anemia]. Can Med Assoc J. 1969;100(24):1151- 4.
104. Gumpel JM. Chronic lymphatic leukaemia presenting as Sjögren's syndrome. Proc R Soc Med. 1972;65(10):877-8.
105. Bán A, Ferenczy S. Sjögren's syndrome associated with chronic lymphocytic leukemia. Panminerva Medica. 1984;26(3): 209-12.
106. Ho CH, Chiang YM, Chong LL, Lin HY, Hwang TS. Development of chronic lymphocytic leukaemia in a case of Sjögren's syndrome with systemic lupus erythematosus. Scand J Haematol 1985;35(2):246-8.
107. Lishner M, Hawker G, Amato D. Chronic lymphocytic leukemia in a patient with systemic lupus erythematosus. Acta Haematol. 1990;84(1):38-9.
108. Lugassy G, Lishner M, Polliack A. Systemic Lupus Erythematosus and Chronic Lymphocytic Leukemia: Rare Coexistence in Three Patients, with Comments on Pathogenesis. Leuk Lymphoma. 1992;8(3): 243.
109. Haubenstock A, Zalusky R. Autoimmune hyperthyroidism and thrombocytopenia developing in a patient with chronic lymphocytic leukemia. Am J Hematol. 1985;19(3):281-3.
110. Beyan C, Kaptan K, Ifran A. Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis. Ann Hematol. 2006;85(11):811-2.
111. Crispino P, Pica R, Angelucci E, Con solazio A, Rivera M, Cassieri C, et al. Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int J Colorectal Dis. 2007;22(5):553-8.
112. Mariette X, Levy Y, Dubreuil ML, Intrator L, Danon F, Brouet JC. Characterization of a human monoclonal autoantibody directed to cardiolipin/beta 2 glycoprotein I produced by chronic lymphocytic leukaemia B cells. Clin Exp Immunol. 1993;94(2):385-90.
113. Pamuk GE, Uyanik MS, Demir M, Tekgündüz E, Turgut B, Soy M. Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis. Leuk Res. 2007;31(8):1149-51.
114. Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S, et al. Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol. 2001; 144(6):1255-61.
115. Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester G-R, Scholze J, et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in VH4-34 expressing single leukemic B cells. Blood. 2002;100(9):3419-22.
116. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003;44(11):1951-5.
117. Anhalt GJ. Paraneoplastic Pemphigus. J Investig Dermatol Symp Proc. 2004;9(1):29- 33.
118. Yegin ZA, Yagci M, Haznedar R. Cold agglutinin disease with IgG monoclonal gammopathy in a case of chronic lymphocytic leukemia: An unusual presentation. Transfus Apher Sci. 2009;40(3):219-20.
119. Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre JP, Mignon F. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int. 1992;42(1):127-35.
120. Cicardi M, Beretta A, Colombo M, Gioffre D, Cugno M, Agostoni A. Relevance of lymphoproliferative disorders and of anti- C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol. 1996; 106(3):475-80.
121. Mallouk A, Pham P-TT, Pham P-CT. Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol. 2006;10(4):284-9.
122. Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007;34(8):503-11.
123. Wang L, Bu PD, Yang Y, Chen X, Zhu PX. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363(9408):525-31.
124. Taintor AR, Leiferman KM, Hashimoto T, Ishii N, Zone JJ, Hull CM. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J Am Acad Dermatol. 2007;56(5 Suppl):S73-6.
125. Bain BJ, Catovsky D, Ewan PW. Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature Blymphocytes. Cancer. 1993;72(11):3318-22.